-
Vishal Mega Mart
129.95 134.50(%) -
Reliance Industr
1,425.80 1,115.55(%) -
Infosys
1,647.70 2,006.80(%) -
Sterlite Tech.
119.00 109.09(%) -
HDFC Bank
1,919.55 1,588.50(%) -
Varun Beverages
469.50 419.40(%) -
ICICI Bank
1,417.60 1,101.00(%) -
TCS
3,522.30 4,585.90(%) -
Happiest Minds
674.00 955.00(%) -
Mazagon Dock
3,342.85 3,778.00(%) -
Garden Reach Sh.
3,205.00 3,528.00(%) -
Bharti Airtel
1,847.50 1,373.05(%) -
M & M
2,993.70 2,360.45(%) -
Kotak Mah. Bank
2,129.90 1,679.10(%) -
Tata Motors
672.00 542.55(%) -
Cochin Shipyard
2,244.10 2,977.10(%) -
Hind. Unilever
2,334.10 3,034.50(%) -
Sun Pharma.Inds.
1,641.40 1,461.40(%) -
St Bk of India
790.75 679.65(%) -
HCL Technologies
1,738.00 2,011.00(%)
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
- Overview
- Key Ratios
- Financials
- Shareholding
- Company Info
- Peer Comparison
Biocon Ltd Pharmaceuticals - Indian - Bulk Drugs & Formln
- Indian Private
- BSE Code : 14801.0
- ISIN : INE376G01013
-
Today’s Low
349.85 -
Today’s High
364.65

-
Open
355.00 -
Perv Close
357.25 -
52W Low
291.00 -
52W High
404.70
Key Indicators
-
P/E(TTM)
0.00
-
Mar.Cap (₹Cr.)
42,339.16
-
Div & Yield %
0.35
-
Book Value(₹)
95.98
-
Debt-Equity Ratio
-1.29
-
AGM Date
17-Jun-2025
-
EPS
0.41
-
P/E Ratio
0.00
Financials Ratios
-
Debt-Equity Ratio
0.91
-
Mar.Cap (₹Cr.)
42,339.16
-
RONW (%)
6.89
-
ROCE (%)
6.35
Score Board
-
Equity (₹ in Cr.)
600.30
-
BV (₹)
96.00
-
Sales( ₹ in Cr.)
2,242.60
-
NP (in Cr.)
49.23
-
NP Var(%)
-54.0
-
Div%
25.0
-
CPS (₹)
1.50
-
EPS (₹)
0.40
-
Traded Value (₹ in Lakhs)
42,897.44
-
52 Week High
404.70
-
52 Week Low
291.00
-
Price BSE
357.0
-
Price NSE
357.00
-
Market Capital( in Cr.)
42,897.44
-
P/C Ratio
242.10
-
P/E Ratio
870.60
-
Price Vs.BV
0.40
-
11-Jun-2025( 01:05)
Hot Pursuit - Bioco... - <p>Biocon Ltd is up for a thir...
-
03-Jun-2025( 08:23)
Hot Pursuit - Bioco... - Additionally, its wholly owned...
-
19-May-2025( 01:00)
Hot Pursuit - Bioco... - <p>Biocon Ltd rose for a fifth...
-
16-May-2025( 09:38)
Hot Pursuit - Bioco... - <P> Rivaroxaban is a prescript...
Navigate The Market With Confidence
Your all-in-one destination for expert investment guidance and streamlined portfolio management solutions
Financials
All Values are in (₹Cr)Particulars(INCOME) | 2024 Mar | 2023 Mar | 2022 Mar | 2021 Mar | 2020 Mar | 2019 Mar |
---|---|---|---|---|---|---|
INCOME : | ||||||
Sales Turnover | 2,127.30 | 1,992.90 | 1,738.20 | 2,028.40 | 1,988.40 | 1,785.70 |
Excise Duty | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Sales | 2,127.30 | 1,992.90 | 1,738.20 | 2,028.40 | 1,988.40 | 1,785.70 |
Other Income | 207.50 | 3,134.20 | 187.20 | 150.20 | 366.00 | 422.00 |
Stock Adjustments | 99.10 | -3.20 | 105.80 | -36.70 | 31.40 | 69.10 |
Total Income | 2,433.90 | 5,123.90 | 2,031.20 | 2,141.90 | 2,385.80 | 2,276.80 |
EXPENDITURE : | ||||||
Raw Materials | 1,033.80 | 981.00 | 914.00 | 761.60 | 859.10 | 857.60 |
Power and Fuel Cost | 215.30 | 279.20 | 231.00 | 186.00 | 193.30 | 152.40 |
Employee Cost | 452.30 | 433.80 | 367.70 | 390.20 | 344.80 | 289.10 |
Other Manufacturing Expenses | 155.40 | 127.10 | 130.50 | 147.00 | 118.30 | 104.30 |
Selling and Administration Expenses | 135.00 | 112.20 | 106.70 | 128.40 | 208.40 | 222.40 |
Miscellaneous Expenses | -28.10 | 32.90 | 33.00 | 66.00 | 9.90 | 18.70 |
Employee Benefit Expenses | 452.30 | 433.80 | 367.70 | 390.20 | 344.80 | 289.10 |
Less: Preoperative Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Expenses | 1,963.70 | 1,966.20 | 1,782.90 | 1,679.20 | 1,733.80 | 1,644.50 |
Operating Profit | 470.20 | 3,157.70 | 248.30 | 462.70 | 652.00 | 632.30 |
Interest | 198.80 | 69.60 | 0.40 | 0.40 | 1.20 | 2.60 |
Gross Profit | 271.40 | 3,088.10 | 247.90 | 462.30 | 650.80 | 629.70 |
Depreciation | 121.10 | 116.90 | 108.20 | 103.50 | 98.00 | 92.30 |
Profit Before Tax | 150.30 | 2,971.20 | 139.70 | 358.80 | 552.80 | 537.40 |
Current Tax | 15.10 | 132.70 | 60.70 | 73.50 | 104.40 | 54.60 |
Fringe Benefit tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Deferred Tax | 15.90 | -9.90 | -7.10 | 4.80 | 7.50 | -9.90 |
Reported Net Profit | 119.30 | 2,848.40 | 86.10 | 280.50 | 440.90 | 492.70 |
Extraordinary Items | 13.41 | 2,861.73 | 2.92 | 3.00 | 136.27 | 166.64 |
Adjusted Net Profit | 105.89 | -13.33 | 83.18 | 277.50 | 304.63 | 326.06 |
Adjustment below Net Profit | 30.70 | 29.40 | -59.40 | 30.40 | 22.60 | -51.80 |
P & L Balance brought forward | 9,950.60 | 7,132.80 | 7,106.10 | 6,795.20 | 6,391.80 | 6,020.60 |
Statutory Appropriations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Appropriations | 180.10 | 60.00 | 0.00 | 0.00 | 60.10 | 69.40 |
P & L Balance carried down | 9,920.50 | 9,950.60 | 7,132.80 | 7,106.10 | 6,795.20 | 6,392.10 |
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Preference Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Equity Dividend (%) | 10.00 | 30.00 | 10.00 | 0.00 | 0.00 | 20.00 |
Dividend Per Share(Rs) | 0.50 | 1.50 | 0.50 | 0.00 | 0.00 | 1.00 |
Earnings Per Share-Unit Curr | 0.99 | 23.72 | 0.72 | 2.34 | 3.67 | 8.21 |
Earnings Per Share(Adj)-Unit Curr | 0.99 | 23.72 | 0.72 | 2.34 | 3.67 | 4.11 |
Book Value | 90.88 | 90.91 | 67.40 | 65.88 | 62.80 | 118.58 |
Book Value(Adj)-Unit Curr | 90.88 | 90.91 | 67.40 | 65.88 | 62.80 | 59.29 |